middle.news
BLS Pharmaceuticals Doubles Revenue and Profit in FY26, Secures $50m German Contract
12:36pm on Monday 31st of August, 2026 AEST
•
Pharmaceuticals
Read Story
BLS Pharmaceuticals Doubles Revenue and Profit in FY26, Secures $50m German Contract
12:36pm on Monday 31st of August, 2026 AEST
Key Points
161% revenue growth to $74.2 million
Net profit after tax up 214% to $15.4 million
Secured $50 million two-year German supply agreement
Expanded manufacturing footprint in Australia, UK, and Latin America
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Bls Pharmaceuticals (ASX:BLS)
OPEN ARTICLE